Galena BioPharma (GALE) CEO Mark Ahn continues to shell out big money for obsolete, rarely prescribed drug products. Tuesday, Galena entered into a license agreement with MonoSol Rx for Zuplenz, an oral dissolvable film containing ondansetron, a drug approved to treat nausea and vomiting caused by cancer chemotherapy. Galena is paying $5 million in cash and stock for U.S. marketing rights to Zuplenz. Galena will also owe MonoSol double-digit royalties on Zuplenz net sales, if any accrue.
Hey, check out all the research scientist jobs. Post your resume today!
